Brainstorm seeks early approval for stem cell treatment in canada
TEL AVIV (Reuters) – Israel’s BrainStorm Cell Therapeutics needs early approval in Canada because of its adult stem cell strategy to patients with amyotrophic lateral sclerosis (ALS), a neuro-degenerative disease, before it completes late-stage numerous studies. BrainStorm stated on Tuesday it had signed a contract with CCRM, a Canadian not-for-profit organization that supports growth and …